These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. Baede-van Dijk PA, Hugen PW, Verweij-van Wissen CP, Koopmans PP, Burger DM, Hekster YA. AIDS; 2001 May 25; 15(8):991-8. PubMed ID: 11399981 [Abstract] [Full Text] [Related]
4. Conversion of the HIV protease inhibitor nelfinavir to a bioactive metabolite by human liver CYP2C19. Hirani VN, Raucy JL, Lasker JM. Drug Metab Dispos; 2004 Dec 25; 32(12):1462-7. PubMed ID: 15448116 [Abstract] [Full Text] [Related]
6. Editorial comment on Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients. Merry C. AIDS; 2001 May 25; 15(8):1057-8. PubMed ID: 11399989 [No Abstract] [Full Text] [Related]
7. Influence of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir and its active metabolite. Damle BD, Uderman H, Biswas P, Crownover P, Lin C, Glue P. Br J Clin Pharmacol; 2009 Nov 25; 68(5):682-9. PubMed ID: 19916992 [Abstract] [Full Text] [Related]
8. Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children. Crommentuyn KM, Scherpbier HJ, Kuijpers TW, Mathôt RA, Huitema AD, Beijnen JH. Pediatr Infect Dis J; 2006 Jun 25; 25(6):538-43. PubMed ID: 16732153 [Abstract] [Full Text] [Related]